Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 314 clinical trials
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

malignancies
measurable disease
malignancy
solid tumor
primary tumor
  • 46 views
  • 14 Dec, 2020
  • 62 locations
  • 0 views
  • 26 Jan, 2021
  • 11 locations
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

  • 50 views
  • 01 Apr, 2021
  • 123 locations
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated dose

estrogen
epidermal growth factor receptor
human epidermal growth factor
measurable disease
tumor cells
  • 18 views
  • 26 Jan, 2021
  • 1 location
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR). This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin.

  • 1 views
  • 03 May, 2021
  • 30 locations
Safety Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Malignant Solid Tumors

advanced malignant solid tumors and to explore the pharmacokinetic characteristics of T601, 5-FC, 5-FU, FBAL, which includes PhI study of dose-escalation study and Ph IIa study of extending study.

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Short-Term Fasting: Impact on Toxicity

This partially randomized clinical trial studies short-term fasting in reducing side effects in patients receiving gemcitabine hydrochloride and cisplatin for advanced solid tumors. Short-term fasting before chemotherapy may reduce the side effects caused by chemotherapy. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to …

  • 30 views
  • 23 Jan, 2021
  • 1 location
Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

  • 0 views
  • 25 Jan, 2021
Nanoliposomal Irinotecan (Nal-IRI ONIVYDE ) in Combination With TAS-102 (LONSURF ) in Refractory Solid Tumors

The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an effective regimen that could be applied to various cancers

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Safety Tolerability and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056 mesylate in cancer patients with resistant or refractory solid tumors.

  • 0 views
  • 28 Apr, 2021
  • 2 locations